AGER and vasculitis: However, our findings suggest that PSL application during acute KD has a distinct potential to also ameliorate HMGB-1/RAGE-mediated inflammatory responses in KD vasculitis, which is borne out by the efficacy of glucocorticoids at reducing the incidence of CAA and the number of IVIG non-responders in KD (4–6).